...
机译:皮下注射 ianalumab (VAY736) 在原发性干燥综合征患者中的安全性和有效性:一项随机、双盲、安慰剂对照、2b 期剂量探索试验
Novartis Pharmaceut;
Rheumatol Clin,Scripps Mem Hosp & Res Inst;
Dept Med Rheumatol & Clin Immunol,ChariteHop Bicetre,Univ Paris SaclayDiv Oral Med,Tufts Sch Dent MedDiv Rheumatol,Johns Hopkins Sch MedDept Rheumatol,Univ Hosp Birmingham NHS Fdn TrustChron Dis Res Ctr,Nova Med SchUniv Hosp Santa Maria della Misericordia,Univ UdineDiv Rheumatol & Clin Immunol,Ludwig Maximilians Univ MunchenDept Rheumatol,Liverpool Univ Hosp NHS Fdn Trust;
机译:Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
机译:Correction to Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial (The Lancet Neurology (2022) 21(5) (417–427), (S1474442222000771), (10.1016/S1474-4422(22)00077-1))
机译:Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial
机译:POS0692 Ianalumab(Vay736)Sjogren综合征患者的安全性和疗效:随机,安慰剂控制,第2B期的52个星期的结果